Logo

Myriad's Stock Edges Up After Split

Mar 26, 2009

NEW YORK (GenomeWeb News) – Shares of Myriad Genetics were trading up 2 percent at $45.44 in mid-afternoon trade on the Nasdaq following the two-for-one split of its shares before the market opened today.

The Salt Lake City-based molecular diagnostics firm announced the split last month. Following the split, it has around 95 million shares outstanding.

The split will alter the number of shares distributed to current shareholders in Myriad Pharmaceuticals, the proposed spinoff of Myriad's drug development business, which is expected to take place in the second quarter. Myriad has initially intended to grant its shareholders a half share of Myriad Pharmaceuticals stock for each share of Myriad Genetics held. Now, the firm expects to issue one quarter of a share in the new entity.

Filed under

Diagnostics
Drug Discovery & Development
drug development
Myriad
Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.